Risk Reduction with Extended Letrozole Therapy

Introduction to Extended Therapy Benefits

The National Comprehensive Cancer Network recommends that extending letrozole from 3 years to 10 years reduces the risk of disease recurrence by approximately 34% based on the MA.17R trial, which showed 5-year disease-free survival of 95% with 10 years of treatment versus 91% with 5 years (hazard ratio 0.66), translating to an absolute risk reduction of 4% over 5 years 1, 2
The American Society of Clinical Oncology suggests that 3 years of anastrozole after 5 years of tamoxifen reduced recurrence risk by 38% compared to stopping at 5 years (HR 0.62; 95% CI 0.40-0.96) 1, 2

Disease-free survival at 5 years was 95% with extended letrozole (10 years total) versus 91% with placebo (5 years total), with a hazard ratio for recurrence of 0.66 (95% CI 0.48-0.91), representing a 34% relative risk reduction 1, 2
The hazard ratio for recurrence was 0.66, indicating a 34% reduction in recurrence risk 1, 2

Extended letrozole therapy prevents new breast cancers in the opposite breast, with an annual incidence of contralateral breast cancer of 0.21% with 10 years of letrozole versus 0.49% with 5 years, and a hazard ratio of 0.42 (95% CI 0.22-0.81), representing a 58% relative risk reduction 1, 2

Extended letrozole therapy does not improve overall survival, with 5-year overall survival of 93% with extended letrozole versus 94% with placebo (HR 0.97; P=0.83) 1, 2, 3, 4

Node-positive patients derive the most substantial benefit from extended therapy and should be offered extended therapy up to 10 years total 3, 4
High-risk node-negative patients (young age, high-grade tumors) may also benefit from extended therapy 1, 3, 4
Low-risk node-negative patients should not routinely receive extended therapy, as absolute benefits are narrow and may not justify ongoing toxicity 3

Extended letrozole significantly increases bone-related adverse events, including bone pain (18% vs 14%), fractures (14% vs 9%), and new-onset osteoporosis (11% vs 6%) 1, 2, 5, 4
Extended letrozole may also increase the risk of cardiovascular events, with a trend toward increased risk (OR 1.18) 3, 4
Quality of life may worsen with extended letrozole, particularly in physical role functioning compared to placebo 6, 3, 4

The National Comprehensive Cancer Network recommends 7.5-10 years total for high-risk patients 2, 5
The American Society of Clinical Oncology recommends no more than 10 years of total endocrine treatment 3, 4
Do not extend therapy beyond 10 years total, as there is no evidence supporting benefit beyond this duration and toxicity accumulates 3, 4